New Delhi (SunstarTV Bureau): Serum Institute of India (SII), the world’s largest vaccine maker, on Wednesday announced a price of Rs 600 per dose for COVID vaccine supplies to private hospitals and Rs 400 per dose to state governments.
In a statement posted on its Twitter handle, SII said it will address the limited capacity by scaling up the vaccine production over the next two months.
“Going ahead, 50 per cent of our capacities will be served to the Government of India’s vaccination programme, and the remaining 50 per cent of the capacity will be for the state governments and private hospitals,” it said.
SII said Covishield vaccine will be available to state governments for Rs 400 per dose and to private hospitals at Rs 600 per dose.
Covishield comprises over 90 pc of 12.76 cr COVID vaccines administered so far
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday.
Of this, 15 states and union territories have only given Covishield, being manufactured by the Pune-based Serum Instiute of India. The other vaccine being administered in India is the indigenous Covaxin from Bharat Biotech in Hyderabad.
Giving details, of the 127,605,870 COVID-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield while 1,15,40,763 are of Covaxin, according to the government’s CO-WIN portal.
Moreover, about 15 states and union territories, including Goa, Chandigarh and Jammu and Kashmir, have administered only Covishield to its beneficiaries.
Experts said Covishield is being produced at a much higher scale than Covaxin due to which its availability is more.
Dr Samiran Panda, the Head of Epidemiology and Communicable Diseases at the Indian Council of Medical Research, said soon the production of Covaxin will be ramped up.
“Following which, the vaccine production capacity will increase significantly,” he said.
Bharat Biotech on Tuesday said capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore, to reach approximately 700 million doses per year.
The Department of Biotechnology is also providing financial support as grants to vaccine manufacturing facilities for enhanced production capacities.
“The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021 i.e increasing the production from 10 million vaccine doses in April, 2021 to 60-70 million vaccine dose per month in July-August,” said the ministry of science and technology in a statement on Monday.
India granted emergency use authorisation to Covaxin and Covishield, following which the vaccination drive started in the country on January 16.
Prime Minister Narendra Modi and External Affairs Minister S Jaishankar were among those administered Bharat Biotech’s Covaxin.
(Sources: IANS)
